{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:05:36Z","timestamp":1775091936774,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T00:00:00Z","timestamp":1511481600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s40520-017-0861-1","type":"journal-article","created":{"date-parts":[[2017,11,24]],"date-time":"2017-11-24T01:07:26Z","timestamp":1511485646000},"page":"111-117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)"],"prefix":"10.1007","volume":"30","author":[{"given":"Olivier","family":"Bruy\u00e8re","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasser M.","family":"Al-Daghri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine M.","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-752X","authenticated-orcid":false,"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,24]]},"reference":[{"key":"861_CR1","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/s0140-6736(12)61729-2","volume":"380","author":"T Vos","year":"2012","unstructured":"Vos T, Flaxman AD, Naghavi M et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163\u20132196. \n                        https:\/\/doi.org\/10.1016\/s0140-6736(12)61729-2","journal-title":"Lancet"},{"key":"861_CR2","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1136\/annrheumdis-2013-204763","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, Smith E, Hoy D et al (2014) The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:1323\u20131330. \n                        https:\/\/doi.org\/10.1136\/annrheumdis-2013-204763","journal-title":"Ann Rheum Dis"},{"key":"861_CR3","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(11)60243-2","volume":"377","author":"JW Bijlsma","year":"2011","unstructured":"Bijlsma JW, Berenbaum F, Lafeber FP (2011) Osteoarthritis: an update with relevance for clinical practice. Lancet 377:2115\u20132126. \n                        https:\/\/doi.org\/10.1016\/S0140-6736(11)60243-2","journal-title":"Lancet"},{"key":"861_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-017-0784-x","author":"H Nur","year":"2017","unstructured":"Nur H, Sertkaya BS, Tuncer T (2017) Determinants of physical functioning in women with knee osteoarthritis. Aging Clin Exp Res. \n                        https:\/\/doi.org\/10.1007\/s40520-017-0784-x","journal-title":"Aging Clin Exp Res"},{"key":"861_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40520-017-0780-1","author":"A Neuprez","year":"2017","unstructured":"Neuprez A, Neuprez AH, Kurth W et al (2017) Profile of osteoarthritic patients undergoing hip or knee arthroplasty, a step toward a definition of the \u201cneed for surgery\u201d. Aging Clin Exp Res. \n                        https:\/\/doi.org\/10.1007\/s40520-017-0780-1","journal-title":"Aging Clin Exp Res"},{"key":"861_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semarthrit.2014.05.014","volume":"44","author":"O Bruyere","year":"2014","unstructured":"Bruyere O, Cooper C, Pelletier JP et al (2014) An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 44:253\u2013263. \n                        https:\/\/doi.org\/10.1016\/j.semarthrit.2014.05.014","journal-title":"Semin Arthritis Rheum"},{"key":"861_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.joca.2014.01.003","volume":"22","author":"TE McAlindon","year":"2014","unstructured":"McAlindon TE, Bannuru RR, Sullivan MC et al (2014) OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil 22:363\u2013388. \n                        https:\/\/doi.org\/10.1016\/j.joca.2014.01.003","journal-title":"Osteoarthr Cartil"},{"key":"861_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.21596","volume":"64","author":"MC Hochberg","year":"2012","unstructured":"Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 64:465\u2013474. \n                        https:\/\/doi.org\/10.1002\/acr.21596","journal-title":"Arthritis Care Res"},{"key":"861_CR9","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1136\/ard.2003.011742","volume":"62","author":"KM Jordan","year":"2003","unstructured":"Jordan KM, Arden NK, Doherty M et al (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62:1145\u20131155. \n                        https:\/\/doi.org\/10.1136\/ard.2003.011742","journal-title":"Ann Rheum Dis"},{"key":"861_CR10","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1185\/03007995.2015.1027183","volume":"31","author":"JY Reginster","year":"2015","unstructured":"Reginster JY, Cooper C, Hochberg M et al (2015) Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Curr Med Res Opin 31:1041\u20131045. \n                        https:\/\/doi.org\/10.1185\/03007995.2015.1027183","journal-title":"Curr Med Res Opin"},{"key":"861_CR11","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.3390\/molecules20034277","volume":"20","author":"J Martel-Pelletier","year":"2015","unstructured":"Martel-Pelletier J, Farran A, Montell E et al (2015) Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules 20:4277\u20134289. \n                        https:\/\/doi.org\/10.3390\/molecules20034277","journal-title":"Molecules"},{"key":"861_CR12","unstructured":"EMA (2007) European Medicines Agency, Coordination Group for Mutual Recognition and Decentralised Procedures\u2014Human. Overview of biological active molecules of non-recombinant origin, June 2007. \n                        http:\/\/www.hma.eu\/fileadmin\/dateien\/Human_Medicines\/CMD_h_\/procedural_guidance\/Compilation_Biological_Active_Substance_non-recombinant_origin.pdf\n                        \n                    . Accessed 25 Sept 2017"},{"key":"861_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1055\/s-0031-1300105","volume":"51","author":"I Setnikar","year":"2001","unstructured":"Setnikar I, Rovati LC (2001) Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung 51:699\u2013725. \n                        https:\/\/doi.org\/10.1055\/s-0031-1300105","journal-title":"Arzneimittelforschung"},{"key":"861_CR14","unstructured":"EMA (2014) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA\/CHMP\/BMWP\/42832\/05 Rev.1. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/01\/WC500180219.pdf\n                        \n                    . Accessed 07 Aug 2017"},{"key":"861_CR15","unstructured":"Senin P, Makovec F, Rovati L (1987) Stable compounds of glucosamine sulfate. USA Patent 4642340"},{"key":"861_CR16","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.joca.2005.07.009","volume":"13","author":"S Persiani","year":"2005","unstructured":"Persiani S, Roda E, Rovati LC et al (2005) Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthr Cartil 13:1041\u20131049. \n                        https:\/\/doi.org\/10.1016\/j.joca.2005.07.009","journal-title":"Osteoarthr Cartil"},{"key":"861_CR17","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.joca.2007.01.019","volume":"15","author":"S Persiani","year":"2007","unstructured":"Persiani S, Rotini R, Trisolino G et al (2007) Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthr Cartil 15:764\u2013772. \n                        https:\/\/doi.org\/10.1016\/j.joca.2007.01.019","journal-title":"Osteoarthr Cartil"},{"key":"861_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.joca.2009.10.013","volume":"18","author":"CG Jackson","year":"2010","unstructured":"Jackson CG, Plaas AH, Sandy JD et al (2010) The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthr Cartil 18:297\u2013302. \n                        https:\/\/doi.org\/10.1016\/j.joca.2009.10.013","journal-title":"Osteoarthr Cartil"},{"key":"861_CR19","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1056\/NEJM198905183202006","volume":"320","author":"D Hamerman","year":"1989","unstructured":"Hamerman D (1989) The biology of osteoarthritis. N Engl J Med 320:1322\u20131330. \n                        https:\/\/doi.org\/10.1056\/NEJM198905183202006","journal-title":"N Engl J Med"},{"key":"861_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1759720X12437753","volume":"4","author":"LC Rovati","year":"2012","unstructured":"Rovati LC, Girolami F, Persiani S (2012) Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis 4:167\u2013180. \n                        https:\/\/doi.org\/10.1177\/1759720X12437753","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"861_CR21","doi-asserted-by":"publisher","first-page":"939265","DOI":"10.1155\/2011\/939265","volume":"2011","author":"R Chiusaroli","year":"2011","unstructured":"Chiusaroli R, Piepoli T, Zanelli T et al (2011) Experimental pharmacology of glucosamine sulfate. Int J Rheumatol 2011:939265. \n                        https:\/\/doi.org\/10.1155\/2011\/939265","journal-title":"Int J Rheumatol"},{"key":"861_CR22","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/art.22728","volume":"56","author":"SC Vlad","year":"2007","unstructured":"Vlad SC, LaValley MP, McAlindon TE et al (2007) Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 56:2267\u20132277. \n                        https:\/\/doi.org\/10.1002\/art.22728","journal-title":"Arthritis Rheum"},{"key":"861_CR23","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1002\/art.22852","volume":"56","author":"JY Reginster","year":"2007","unstructured":"Reginster JY (2007) The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 56:2105\u20132110. \n                        https:\/\/doi.org\/10.1002\/art.22852","journal-title":"Arthritis Rheum"},{"key":"861_CR24","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/acr.22376","volume":"66","author":"P Eriksen","year":"2014","unstructured":"Eriksen P, Bartels EM, Altman RD et al (2014) Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken) 66:1844\u20131855. \n                        https:\/\/doi.org\/10.1002\/acr.22376","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"861_CR25","doi-asserted-by":"publisher","first-page":"CD002946","DOI":"10.1002\/14651858.CD002946.pub2","volume":"2","author":"TE Towheed","year":"2009","unstructured":"Towheed TE, Maxwell L, Anastassiades TP et al (2009) Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2:CD002946. \n                        https:\/\/doi.org\/10.1002\/14651858.CD002946.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"861_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/art.22371","volume":"56","author":"G Herrero-Beaumont","year":"2007","unstructured":"Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M et al (2007) Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 56:555\u2013567. \n                        https:\/\/doi.org\/10.1002\/art.22371","journal-title":"Arthritis Rheum"},{"key":"861_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0140-6736(00)03610-2","volume":"357","author":"JY Reginster","year":"2001","unstructured":"Reginster JY, Deroisy R, Rovati LC et al (2001) Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357:251\u2013256. \n                        https:\/\/doi.org\/10.1016\/S0140-6736(00)03610-2","journal-title":"Lancet"},{"key":"861_CR28","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1001\/archinte.162.18.2113","volume":"162","author":"K Pavelka","year":"2002","unstructured":"Pavelka K, Gatterova J, Olejarova M et al (2002) Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162:2113\u20132123","journal-title":"Arch Intern Med"},{"key":"861_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"861_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211149","author":"J Runhaar","year":"2017","unstructured":"Runhaar J, Rozendaal RM, Middelkoop MV et al (2017) Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trail bank. Ann Rheum Dis. \n                        https:\/\/doi.org\/10.1136\/annrheumdis-2017-211149","journal-title":"Ann Rheum Dis"},{"key":"861_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212251","author":"JL Reginster","year":"2017","unstructured":"Reginster JL, Bruyere O, Cooper C (2017) Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Ann Rheum Dis. \n                        https:\/\/doi.org\/10.1136\/annrheumdis-2017-212251","journal-title":"Ann Rheum Dis"},{"key":"861_CR32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1586\/ecp.09.17","volume":"2","author":"RD Altman","year":"2009","unstructured":"Altman RD (2009) Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations. Expert Rev Clin Pharmacol 2:359\u2013371. \n                        https:\/\/doi.org\/10.1586\/ecp.09.17","journal-title":"Expert Rev Clin Pharmacol"},{"key":"861_CR33","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.joca.2010.01.013","volume":"18","author":"W Zhang","year":"2010","unstructured":"Zhang W, Nuki G, Moskowitz RW et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18:476\u2013499. \n                        https:\/\/doi.org\/10.1016\/j.joca.2010.01.013","journal-title":"Osteoarthr Cartil"},{"key":"861_CR34","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejpain.2006.02.013","volume":"11","author":"JM Bjordal","year":"2007","unstructured":"Bjordal JM, Klovning A, Ljunggren AE (2007) Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 11:125\u2013138. \n                        https:\/\/doi.org\/10.1016\/j.ejpain.2006.02.013","journal-title":"Eur J Pain"},{"key":"861_CR35","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/s0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Bhala N, Emberson J, Merhi A et al (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:769\u2013779. \n                        https:\/\/doi.org\/10.1016\/s0140-6736(13)60900-9","journal-title":"Lancet"},{"key":"861_CR36","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2165\/11633470-000000000-00000","volume":"35","author":"J Castellsague","year":"2012","unstructured":"Castellsague J, Riera-Guardia N, Calingaert B et al (2012) Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 35:1127\u20131146. \n                        https:\/\/doi.org\/10.2165\/11633470-000000000-00000","journal-title":"Drug Saf"},{"key":"861_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ctim.2008.08.004","volume":"17","author":"RM Lauder","year":"2009","unstructured":"Lauder RM (2009) Chondroitin sulphate: a complex molecule with potential impacts on a wide range of biological systems. Complement Ther Med 17:56\u201362. \n                        https:\/\/doi.org\/10.1016\/j.ctim.2008.08.004","journal-title":"Complement Ther Med"},{"key":"861_CR38","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1002\/jps.20997","volume":"96","author":"N Volpi","year":"2007","unstructured":"Volpi N (2007) Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci 96:3168\u20133180. \n                        https:\/\/doi.org\/10.1002\/jps.20997","journal-title":"J Pharm Sci"},{"key":"861_CR39","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1211\/jpp\/61.10.0002","volume":"61","author":"N Volpi","year":"2009","unstructured":"Volpi N (2009) Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol 61:1271\u20131280. \n                        https:\/\/doi.org\/10.1211\/jpp\/61.10.0002","journal-title":"J Pharm Pharmacol"},{"key":"861_CR40","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jama.283.11.1469","volume":"283","author":"TE McAlindon","year":"2000","unstructured":"McAlindon TE, LaValley MP, Gulin JP et al (2000) Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283:1469\u20131475","journal-title":"JAMA"},{"key":"861_CR41","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1001\/archinte.163.13.1514","volume":"163","author":"F Richy","year":"2003","unstructured":"Richy F, Bruyere O, Ethgen O et al (2003) Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 163:1514\u20131522. \n                        https:\/\/doi.org\/10.1001\/archinte.163.13.1514","journal-title":"Arch Intern Med"},{"key":"861_CR42","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2174\/1874312901206010183","volume":"6","author":"H Schneider","year":"2012","unstructured":"Schneider H, Maheu E, Cucherat M (2012) Symptom-modifying effect of chondroitin sulfate in knee osteoarthritis: a meta-analysis of randomized placebo-controlled trials performed with structum((R)). Open Rheumatol J 6:183\u2013189. \n                        https:\/\/doi.org\/10.2174\/1874312901206010183","journal-title":"Open Rheumatol J"},{"key":"861_CR43","doi-asserted-by":"crossref","first-page":"580","DOI":"10.7326\/0003-4819-146-8-200704170-00009","volume":"146","author":"S Reichenbach","year":"2007","unstructured":"Reichenbach S, Sterchi R, Scherer M et al (2007) Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 146:580\u2013590","journal-title":"Ann Intern Med"},{"key":"861_CR44","doi-asserted-by":"publisher","first-page":"c4675","DOI":"10.1136\/bmj.c4675","volume":"341","author":"S Wandel","year":"2010","unstructured":"Wandel S, Juni P, Tendal B et al (2010) Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 341:c4675. \n                        https:\/\/doi.org\/10.1136\/bmj.c4675","journal-title":"BMJ"},{"key":"861_CR45","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1211\/jpp\/61.10.0001","volume":"61","author":"KD Rainsford","year":"2009","unstructured":"Rainsford KD (2009) Importance of pharmaceutical composition and evidence from clinical trials and pharmacological studies in determining effectiveness of chondroitin sulphate and other glycosaminoglycans: a critique. J Pharm Pharmacol 61:1263\u20131270. \n                        https:\/\/doi.org\/10.1211\/jpp\/61.10.0001","journal-title":"J Pharm Pharmacol"},{"key":"861_CR46","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1136\/annrheumdis-2013-203954","volume":"74","author":"M Fransen","year":"2015","unstructured":"Fransen M, Agaliotis M, Nairn L et al (2015) Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 74:851\u2013858. \n                        https:\/\/doi.org\/10.1136\/annrheumdis-2013-203954","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"861_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.joca.2012.09.017","volume":"21","author":"B Zegels","year":"2013","unstructured":"Zegels B, Crozes P, Uebelhart D et al (2013) Equivalence of a single dose (1200\u00a0mg) compared to a three-time a day dose (400\u00a0mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthr Cartil 21(1):22\u201327. \n                        https:\/\/doi.org\/10.1016\/j.joca.2012.09.017","journal-title":"Osteoarthr Cartil"},{"key":"861_CR48","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/art.24255","volume":"60","author":"A Kahan","year":"2009","unstructured":"Kahan A, Uebelhart D, De Vathaire F et al (2009) Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 60:524\u2013533. \n                        https:\/\/doi.org\/10.1002\/art.24255","journal-title":"Arthritis Rheum"},{"key":"861_CR49","doi-asserted-by":"publisher","first-page":"CD005614","DOI":"10.1002\/14651858.CD005614.pub2","volume":"1","author":"JA Singh","year":"2015","unstructured":"Singh JA, Noorbaloochi S, MacDonald R et al (2015) Chondroitin for osteoarthritis. Cochrane Database Syst Rev 1:CD005614. \n                        https:\/\/doi.org\/10.1002\/14651858.CD005614.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"861_CR50","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1136\/annrheumdis-2016-210860","volume":"76","author":"JY Reginster","year":"2017","unstructured":"Reginster JY, Dudler J, Blicharski T et al (2017) Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis 76:1537\u20131543. \n                        https:\/\/doi.org\/10.1136\/annrheumdis-2016-210860","journal-title":"Ann Rheum Dis"},{"key":"861_CR51","unstructured":"AHRQ (2017) Agency for healthcare research and quality, treatment of osteoarthritis of the knee: an update review, May 2017. Comparative Effectiveness Review Number 190. AHRQ Publication No. 17-EHC011-EF"},{"key":"861_CR52","unstructured":"EMA (2010) Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. CPMP\/EWP\/784\/97 Rev.1. \n                        http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003440.pdf\n                        \n                    . Accessed 07 Aug 2017"},{"key":"861_CR53","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.joca.2015.07.001","volume":"23","author":"JY Reginster","year":"2015","unstructured":"Reginster JY, Reiter-Niesert S, Bruyere O et al (2015) Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. Osteoarthr Cartil 23:2086\u20132093. \n                        https:\/\/doi.org\/10.1016\/j.joca.2015.07.001","journal-title":"Osteoarthr Cartil"},{"key":"861_CR54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1947603514554992","volume":"6","author":"BA Christiansen","year":"2015","unstructured":"Christiansen BA, Bhatti S, Goudarzi R et al (2015) Management of osteoarthritis with avocado\/soybean unsaponifiables. Cartilage 6:30\u201344. \n                        https:\/\/doi.org\/10.1177\/1947603514554992","journal-title":"Cartilage"},{"key":"861_CR55","first-page":"825","volume":"64","author":"F Blotman","year":"1997","unstructured":"Blotman F, Maheu E, Wulwik A et al (1997) Efficacy and safety of avocado\/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed 64:825\u2013834","journal-title":"Rev Rhum Engl Ed"},{"key":"861_CR56","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/1529-0131(199801)41:1<81::AID-ART11>3.0.CO;2-9","volume":"41","author":"E Maheu","year":"1998","unstructured":"Maheu E, Mazieres B, Valat JP et al (1998) Symptomatic efficacy of avocado\/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum 41:81\u201391. \n                        https:\/\/doi.org\/10.1002\/1529-0131(199801)41:1<81::AID-ART11>3.0.CO;2-9","journal-title":"Arthritis Rheum"},{"key":"861_CR57","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/030097401316909602","volume":"30","author":"T Appelboom","year":"2001","unstructured":"Appelboom T, Schuermans J, Verbruggen G et al (2001) Symptoms modifying effect of avocado\/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol 30:242\u2013247","journal-title":"Scand J Rheumatol"},{"key":"861_CR58","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/art1.10239","volume":"47","author":"M Lequesne","year":"2002","unstructured":"Lequesne M, Maheu E, Cadet C et al (2002) Structural effect of avocado\/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum 47:50\u201358","journal-title":"Arthritis Rheum"},{"key":"861_CR59","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/annrheumdis-2012-202485","volume":"73","author":"E Maheu","year":"2014","unstructured":"Maheu E, Cadet C, Marty M et al (2014) Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis 73:376\u2013384. \n                        https:\/\/doi.org\/10.1136\/annrheumdis-2012-202485","journal-title":"Ann Rheum Dis"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40520-017-0861-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-017-0861-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-017-0861-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T08:18:30Z","timestamp":1518682710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40520-017-0861-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,24]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["861"],"URL":"https:\/\/doi.org\/10.1007\/s40520-017-0861-1","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,24]]}}}